GTX Medical

GTX Medical this week said it appointed Dave Marver as chief executive officer.

Marver has more than 15 years of experience in various leadership roles at Medtronic and has also held leadership positions at Cardiac Science Corporation and has co-founded two startup companies in orthopedics and sports technologies.

“GTX is the clear leader in developing technologies to transform the lives of people living with spinal cord injury,” Marver said in a news release. “It is a privilege to join the GTX team. I look forward to driving the advancement and eventual commercialization of these amazing technologies, starting with the U.S. clinical trial of our non-invasive therapy to improve movement in upper extremities later this year.”

GTX is currently developing non-invasive and implantable neuromodulation technologies for people with spinal cord injuries.

“It is an achievement for GTX to bring a CEO of Dave’s caliber on board to lead the strong team we hav…

GTX Medical this week said it received FDA breakthrough device designation for its Go-2 targeted epidural spinal stimulation system.

The system is designed to promote the recovery of leg motor functions and neurological control in adults that have spinal cord injuries and paralysis. It improves the reconnection of the brain with paralyzed muscles and individuals with dramatic spinal cord injury.

“The FDA Breakthrough Device Designation is an important regulatory milestone and underscores the transformative potential of the Go-2 system and the unmet medical need it addresses,” chairperson of the board Jan Öhrström said in a news release. “With Breakthrough Device Designation for the implantable Go-2 system and for the non-invasive LIFT technology, we are now on an accelerated pathway. Both designations support our aim to expeditiously bring GTX’ innovative therapies for improving functional recovery, enhancing quality of life and independence of people with spin…